TY-2136b

A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

Arms / Cohorts

Dose Escalation:NTRK 1-3 Gene

Accepting patients

EXPERIMENTAL: Escalation stage

Accepting patients

EXPERIMENTAL: Expansion stage

Accepting patients

Dose Expansion:NTRK 1-3 Gene

Not yet accepting

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(831) 888-0898

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.